GALT Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3984R |
| Product Name | GALT Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse, Rat |
| Predicted Reactivity | Human, Cow |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human GALT |
| Immunogen Range | 251-350/379 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 2592 |
| Subcellular location | Cytoplasm |
| Synonyms | Gal 1 P uridylyltransferase; Galactose 1 phosphate uridyl transferase; Galactose 1 phosphate uridylyltransferase; UDP glucose hexose 1 phosphate uridylyltransferase; GALT_HUMAN. |
| Background | GALT (Galactose 1 phosphate uridyl transferase) catalyzes the second step of the Leloir pathway of galactose metabolism, namely the conversion of UDP glucose + galactose 1 phosphate to glucose 1 phosphate + UDP galactose. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet. The pathophysiology of galactosemia has not been clearly defined. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |